Having trouble viewing this email? View in your browser.

16 January 2018

Dear colleagues,

The deadline for registration of the basic module to attain EUCIC’s Infection Prevention and Control Certificate is on 14 February 2018. Make sure to reserve your spot for this exciting training opportunity!

Applications for the 2018 Mayo Clinic observership are now open. There is only one spot available to a Young Scientist Member so click here to apply before 31 January. Please note that the application platform for other observership visits is not yet open. We will provide you with an update on this in the coming weeks.

Your ESCMID communications editors


2018 Excellence Award Lecture at ECCMID on Sunday 22 April

The winners of the 2018 Excellence Awards are Claudio Viscoli from the University of Genova in Italy and Dimitrios P. Kontoyiannis from the University of Texas M. D. Anderson Cancer Center in the United States. Kontoyiannis is an international expert in clinical and experimental mycology. His research group is credited for sustained and impactful contributions to medical and translational mycology through advances in antifungal pharmacology, study host defences against fungi, novel diagnostics, clinical trials, dedicated mentoring, organizational service and life-saving patient care. Viscoli is an expert for infectious disease in children and adults with special expertise in infections in compromised host, fungal infections, infections in cancer and neutropenia, infections in liver transplant recipients, opportunistic infections in HIV and HIV vertical transmission. They will receive their awards on Sunday, 22 April 2018 at a dedicated awards session at ECCMID in Madrid.

› Read more

CMI highlight: researchers update CDI treatment algorithm

Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both in healthcare facilities and the community. The recurrence rate of C. difficile infection (CDI) remains high, up to 20%. Researchers from the Netherlands reviewed novel treatments and approaches for CDI, focusing on new antibiotics, antibiotic inactivators, monoclonal antibodies (mAbs), and gut microbiota modulating therapies. The researchers propose that vancomycin orally will become the first choice instead of metronidazole when antibiotic treatment for CDI is necessary and the severity of the disease difficult to assess. Fidaxomicin is a good alternative, especially in patients at risk of developing a relapse. Vancomycin combined with FMT remains the primary therapy for multiple recurrent CDI. They anticipate that new medication that protects the gut microbiota will be further developed and tested to prevent CDI during antibiotic therapy. ESCMID will publish an update on its 2014 CDI guideline in the coming weeks.

› Read more

Antimicrobial stewardship course in Spain before ECCMID

The ESCMID study group for antimicrobial stewardship is organizing the postgraduate education course Antimicrobial Stewardship: Implementing the Change in San Lorenzo de el Escorial, Spain from 19 – 20 April 2018, right before ECCMID opens its doors on 21 April. Participants will learn about the differential aspects of antimicrobial stewardship in various settings, its  scientific background, the sociocultural, ethical and behavioural aspects, the relevance of the quality management/implementation, the barriers, the basic principles of bacterial resistance, and antimicrobial consumption surveillance. Participants have until 2 February 2018 if they want to apply for an attendance grant.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.